Cargando…

An exploratory analysis of MR-guided fractionated stereotactic radiotherapy in patients with brain metastases

PURPOSE: To assess the feasibility and potential benefits of online adaptive MR-guided fractionated stereotatic radiotherapy (FSRT) in patients with brain metastases (BMs). METHODS AND MATERIALS: Twenty-eight consecutive patients with BMs were treated with FSRT of 30 Gy in 5 fractions on the 1.5 T M...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Shouliang, Liu, Biaoshui, Zheng, Shiyang, Wang, Daquan, Liu, Mingzhi, Liu, Hongdong, Zhang, Pengxin, Peng, Kangqiang, He, Haoqiang, Zhou, Rui, Guo, Jinyu, Qiu, Bo, Huang, Xiaoyan, Liu, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996243/
https://www.ncbi.nlm.nih.gov/pubmed/36910023
http://dx.doi.org/10.1016/j.ctro.2023.100602
_version_ 1784902999057891328
author Ding, Shouliang
Liu, Biaoshui
Zheng, Shiyang
Wang, Daquan
Liu, Mingzhi
Liu, Hongdong
Zhang, Pengxin
Peng, Kangqiang
He, Haoqiang
Zhou, Rui
Guo, Jinyu
Qiu, Bo
Huang, Xiaoyan
Liu, Hui
author_facet Ding, Shouliang
Liu, Biaoshui
Zheng, Shiyang
Wang, Daquan
Liu, Mingzhi
Liu, Hongdong
Zhang, Pengxin
Peng, Kangqiang
He, Haoqiang
Zhou, Rui
Guo, Jinyu
Qiu, Bo
Huang, Xiaoyan
Liu, Hui
author_sort Ding, Shouliang
collection PubMed
description PURPOSE: To assess the feasibility and potential benefits of online adaptive MR-guided fractionated stereotatic radiotherapy (FSRT) in patients with brain metastases (BMs). METHODS AND MATERIALS: Twenty-eight consecutive patients with BMs were treated with FSRT of 30 Gy in 5 fractions on the 1.5 T MR-Linac. The FSRT fractions employed daily MR scans and the contours were utilized to create each adapted plan. The brain lesions and perilesional edema were delineated on MR images of pre-treatment simulation (Fx0) and all fractions (Fx1, Fx2, Fx3, Fx4 and Fx5) to evaluate the inter-fractional changes. These changes were quantified using absolute/relative volume, Dice similarity coefficient (DSC) and Hausdorff distance (HD) metrics. Planning target volume (PTV) coverage and organ at risk (OAR) constraints were used to compare non-adaptive and adaptive plans. RESULTS: A total of 28 patients with 88 lesions were evaluated, and 23 patients (23/28, 82.1%) had primary lung adenocarcinoma. Significant tumor volume reduction had been found during FSRT compared to Fx0 for all 88 lesions (median −0.75%, −5.33%, −9.32%, −17.96% and −27.73% at Fx1, Fx2, Fx3, Fx4 and Fx5, p < 0.05). There were 47 (47/88, 53.4%) lesions being accompanied by perilesional edema and the inter-fractional changes were significantly different compared to those without perilesional edema (p < 0.001). Patients with multiple lesions (13/28, 46.4%) had more significant inter-fractional tumor changes than those with single lesion (15/28, 53.6%), including tumor volume reduction and anatomical shift (p < 0.001). PTV coverage of non-adaptive plans was below the prescribed coverage in 26/140 fractions (19%), with 12 (9%) failing by more than 10%. All 140 adaptive fractions met prescribed target coverage. The adaptive plans also had lower dose to whole brain than non-adaptive plans (p < 0.001). CONCLUSIONS: Significant inter-fractional tumor changes could be found during FSRT in patients with BMs treated on the 1.5 T MR-Linac. Daily MR-guided re-optimization of treatment plans showed dosimetric benefit in patients with perilesional edema or multiple lesions.
format Online
Article
Text
id pubmed-9996243
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-99962432023-03-10 An exploratory analysis of MR-guided fractionated stereotactic radiotherapy in patients with brain metastases Ding, Shouliang Liu, Biaoshui Zheng, Shiyang Wang, Daquan Liu, Mingzhi Liu, Hongdong Zhang, Pengxin Peng, Kangqiang He, Haoqiang Zhou, Rui Guo, Jinyu Qiu, Bo Huang, Xiaoyan Liu, Hui Clin Transl Radiat Oncol Original Research Article PURPOSE: To assess the feasibility and potential benefits of online adaptive MR-guided fractionated stereotatic radiotherapy (FSRT) in patients with brain metastases (BMs). METHODS AND MATERIALS: Twenty-eight consecutive patients with BMs were treated with FSRT of 30 Gy in 5 fractions on the 1.5 T MR-Linac. The FSRT fractions employed daily MR scans and the contours were utilized to create each adapted plan. The brain lesions and perilesional edema were delineated on MR images of pre-treatment simulation (Fx0) and all fractions (Fx1, Fx2, Fx3, Fx4 and Fx5) to evaluate the inter-fractional changes. These changes were quantified using absolute/relative volume, Dice similarity coefficient (DSC) and Hausdorff distance (HD) metrics. Planning target volume (PTV) coverage and organ at risk (OAR) constraints were used to compare non-adaptive and adaptive plans. RESULTS: A total of 28 patients with 88 lesions were evaluated, and 23 patients (23/28, 82.1%) had primary lung adenocarcinoma. Significant tumor volume reduction had been found during FSRT compared to Fx0 for all 88 lesions (median −0.75%, −5.33%, −9.32%, −17.96% and −27.73% at Fx1, Fx2, Fx3, Fx4 and Fx5, p < 0.05). There were 47 (47/88, 53.4%) lesions being accompanied by perilesional edema and the inter-fractional changes were significantly different compared to those without perilesional edema (p < 0.001). Patients with multiple lesions (13/28, 46.4%) had more significant inter-fractional tumor changes than those with single lesion (15/28, 53.6%), including tumor volume reduction and anatomical shift (p < 0.001). PTV coverage of non-adaptive plans was below the prescribed coverage in 26/140 fractions (19%), with 12 (9%) failing by more than 10%. All 140 adaptive fractions met prescribed target coverage. The adaptive plans also had lower dose to whole brain than non-adaptive plans (p < 0.001). CONCLUSIONS: Significant inter-fractional tumor changes could be found during FSRT in patients with BMs treated on the 1.5 T MR-Linac. Daily MR-guided re-optimization of treatment plans showed dosimetric benefit in patients with perilesional edema or multiple lesions. Elsevier 2023-02-23 /pmc/articles/PMC9996243/ /pubmed/36910023 http://dx.doi.org/10.1016/j.ctro.2023.100602 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research Article
Ding, Shouliang
Liu, Biaoshui
Zheng, Shiyang
Wang, Daquan
Liu, Mingzhi
Liu, Hongdong
Zhang, Pengxin
Peng, Kangqiang
He, Haoqiang
Zhou, Rui
Guo, Jinyu
Qiu, Bo
Huang, Xiaoyan
Liu, Hui
An exploratory analysis of MR-guided fractionated stereotactic radiotherapy in patients with brain metastases
title An exploratory analysis of MR-guided fractionated stereotactic radiotherapy in patients with brain metastases
title_full An exploratory analysis of MR-guided fractionated stereotactic radiotherapy in patients with brain metastases
title_fullStr An exploratory analysis of MR-guided fractionated stereotactic radiotherapy in patients with brain metastases
title_full_unstemmed An exploratory analysis of MR-guided fractionated stereotactic radiotherapy in patients with brain metastases
title_short An exploratory analysis of MR-guided fractionated stereotactic radiotherapy in patients with brain metastases
title_sort exploratory analysis of mr-guided fractionated stereotactic radiotherapy in patients with brain metastases
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996243/
https://www.ncbi.nlm.nih.gov/pubmed/36910023
http://dx.doi.org/10.1016/j.ctro.2023.100602
work_keys_str_mv AT dingshouliang anexploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases
AT liubiaoshui anexploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases
AT zhengshiyang anexploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases
AT wangdaquan anexploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases
AT liumingzhi anexploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases
AT liuhongdong anexploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases
AT zhangpengxin anexploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases
AT pengkangqiang anexploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases
AT hehaoqiang anexploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases
AT zhourui anexploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases
AT guojinyu anexploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases
AT qiubo anexploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases
AT huangxiaoyan anexploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases
AT liuhui anexploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases
AT dingshouliang exploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases
AT liubiaoshui exploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases
AT zhengshiyang exploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases
AT wangdaquan exploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases
AT liumingzhi exploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases
AT liuhongdong exploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases
AT zhangpengxin exploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases
AT pengkangqiang exploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases
AT hehaoqiang exploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases
AT zhourui exploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases
AT guojinyu exploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases
AT qiubo exploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases
AT huangxiaoyan exploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases
AT liuhui exploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases